Discovered at Mayo Clinic, rHIgM22 Represents Potential New Approach to MS Treatment ROCHESTER, Minn. & ARDSLEY, N.Y.–(BUSINESS WIRE)–Apr. 23, 2013– Mayo Clinic and Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that the first patient has been enrolled in the first clinical trial of rHIgM22, a remyelinating antibody being studied for the treatment of multiple sclerosis (MS). [...]
↧